Johnson & Johnson stock has delivered a 69.3% total return over the past five years, while current valuation checks send a mixed message, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside and earnings-based multiples looking less generous.

• Over the last five years, Johnson & Johnson has returned 69.3%, which puts more focus on whether today’s price still offers a margin of safety.
• Progress in higher value medicines, including recent U.S. FDA Priority Review for amivantamab in head and neck cancer, can support cash flow expectations, while ongoing talc litigation and the proposed US$5.5b settlement may weigh on how investors assess long term liabilities.
• The valuation checks are mixed rather than clear…